文献速递头颈部肿瘤放疗姑息放疗与转移瘤

空间分割放疗(Lattice SFRT)在局部晚期大体积不可切除头颈部癌姑息治疗中的应用

Spatially fractionated radiotherapy (Lattice SFRT) in the palliative treatment of locally advanced bulky unresectable head and neck cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-07-30

本研究纳入2022年6月至2023年6月接受Lattice SFRT的19例大体积头颈部癌患者,采用基于VMAT技术的MLC给予2–3次12 Gy照射;19例中16例(84.2%)达客观缓解,17例症状不同程度改善,5例出现RTOG 1级及以上急性毒性,未见3级不良事件。作者认为Lattice SFRT是 bulky 头颈部癌姑息治疗的可行选择。

要点

  • 19例大体积不可切除头颈部癌患者接受Lattice SFRT,中位肿瘤体积208 cc(范围48–701 cc)。
  • 19例中16例(84.2%)达客观缓解,其中10例部分缓解、3例退缩超过75%;17例症状不同程度改善。
  • 5例出现RTOG 1级及以上急性毒性,未见3级不良事件。

核心结论

  • 作者认为Lattice SFRT是 bulky 头颈部癌姑息治疗的可行选择,在姑息场景下可及时缓解症状、改善患者生活质量,治疗毒性处于可接受范围。
  • 作者指出继续优化Lattice SFRT实施与患者选择可从该放疗模式可行性与疗效的进一步数据中获益。

研究设计与样本

  • 单臂研究,报告2022年6月至2023年6月接受Lattice SFRT的局部晚期大体积不可切除头颈部癌患者的安全性与结局。
  • 连续纳入19例符合研究标准的患者,以鳞状细胞癌组织学为主;中位年龄62岁(范围39–79岁),中位肿瘤体积208 cc(范围48–701 cc)。
  • Lattice SFRT采用6 MV光子束、基于MLC的VMAT技术,给予2–3次12 Gy照射;主要终点为症状缓解率与肿瘤缓解率,次要终点为总生存、局部控制及急性和晚期毒性率。

主要发现

  • 全部患者完成放疗;19例中16例(84.2%)达客观缓解,其中10例达部分缓解(PR),3例退缩超过75%。
  • 17例患者症状获得不同程度改善。
  • 5例发生RTOG 1级及以上急性毒性,未观察到3级不良事件。

临床怎么用

  • 作者认为Lattice SFRT可作为大体积头颈部癌姑息治疗的可行选择,在姑息场景下可及时缓解症状并改善生活质量。
  • 作者指出继续优化Lattice SFRT实施与患者选择可受益于该模式可行性与疗效的进一步数据。

局限性

  • 作者指出继续优化Lattice SFRT实施与患者选择可受益于该放疗模式可行性与疗效的进一步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Locally advanced bulky unresectable head neck cancer causes significant tumor mass effects, leading to severe symptoms. This study aims to report the safety and outcomes in patients undergoing Lattice spatially fractionated radiotherapy (Lattice SFRT) for locally advanced bulky unresectable head and neck cancer. METHODS: Patients with bulky head and neck cancer received Lattice SFRT between June 2022 and June 2023. Lattice SFRT was administered in 2-3 fractions of 12 Gy (Gy) using 6-megavolt (MV) photon beams through a multileaf collimator (MLC) based on VMAT technology. The primary endpoints were symptomatic and tumor response rates. Secondary endpoints were overall survival, local control, and acute and late toxicity rates. RESULTS: 19 consecutive patients meeting the study criteria were identified, predominantly with squamous cell carcinoma histology. The median patient age was 62 years (range 39-79 years), and the median tumor volume was 208 cc (cc) (range 48-701 cc). All patients completed radiotherapy. Among all investigated patients, 16 of 19 (84.2 %) patients achieved an objective response, including 10 individuals achieved a partial response (PR), with 3 of them exhibiting regression exceeding 75 %. 17 patients showed symptom improvement to varying degrees. Acute toxicity of Radiation Therapy Oncology Group (RTOG) grade 1 or higher occurred in 5 patients, while no grade 3 adverse events was observed. CONCLUSIONS: Lattice SFRT proves to be a viable treatment option for the palliative management of bulky head and neck cancer. In the palliative setting, Lattice SFRT offers timely symptom relief, enhancing patient quality of life. Treatment toxicity remains within an acceptable range. Continued optimization of Lattice SFRT delivery and patient selection can benefit from further data on the feasibility and efficacy of this radiation modality.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu P, Wang S, Zhou J, et al. Spatially fractionated radiotherapy (Lattice SFRT) in the palliative treatment of locally advanced bulky unresectable head and neck cancer. Clin Transl Radiat Oncol. 2024. PMID: 39219705. doi:10.1016/j.ctro.2024.100830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。